36 results on '"Bourdin, Arnaud"'
Search Results
2. Sacubitril/valsartan has an underestimated impact on the right ventricle in patients with sleep-disordered breathing, especially central sleep apnoea syndrome
- Author
-
Cardelli, Laura Sofia, Magaldi, Mariarosaria, Agullo, Audrey, Richard, Gaetan, Nogue, Erika, Berdague, Philippe, Galiner, Michel, Georger, Frédéric, Picard, François, Prunet, Elvira, Molinari, Nicolas, Bourdin, Arnaud, Jaffuel, Dany, and Roubille, François
- Published
- 2024
- Full Text
- View/download PDF
3. CT Imaging Assessment of Response to Treatment in Allergic Bronchopulmonary Aspergillosis in Adults With Bronchial Asthma
- Author
-
Mal, Hervé, Le Guen, Pierre, Dupin, Clairelyne, Meurice, Jean Claude, Verdaguer, Marion, de Keizer, Joe, Delétage-Métreau, Céline, Le Mao, Raphael, Tromer, Cécile, Fajole, Gaëlle, Rayez, Mélanie, Raymond, Christel Saint, Gheerbrant, Hubert, Badatcheff, Anne, Person, Christine, Macey, Julie, Dermant, Xavier, Boitiaux, Jean-François, Gosset-Woimant, Marine, Metz-Favre, Carine, Degot, Tristan, Poulet, Claire, Popin, Elisabeth, Gamez, Anne Sophie, Boissin, Clément, Prevotat, Anne, Mangiapan, Gilles, Brouquières, Danielle, Le Floch, Hervé, Morisse-Pradier, Hélène, Sattler, Caroline, Muti, Daniela, Germaud, Patrick, Dirou, Stéphanie, Paris, Audrey, Melloni, Boris, Ballouhey, Julia, Bondeelle, Louise, Laurent, Lucie, Belleguic, Chantal, Kerjouan, Mallorie, Deslée, Gaëtan, Dury, Sandra, Bergot, Emmanuel, Magnier, Romain, Morel, Hugues, Lemaire, Bertrand, Tumino, Cécile, Sénéchal, Agathe, Choinier, Pascaline, Parrot, Antoine, Godet, Cendrine, Brun, Anne-Laure, Couturaud, Francis, Laurent, François, Frat, Jean-Pierre, Marchand-Adam, Sylvain, Gagnadoux, Frédéric, Blanchard, Elodie, Taillé, Camille, Philippe, Bruno, Hirschi, Sandrine, Andréjak, Claire, Bourdin, Arnaud, Chenivesse, Cécile, Dominique, Stéphane, Murris-Espin, Marlène, Rivière, Frédéric, Garcia, Gilles, Blanc, François-Xavier, Goupil, François, Bergeron, Anne, Flament, Thomas, Priou, Pascaline, Ragot, Stéphanie, and Cadranel, Jacques
- Published
- 2024
- Full Text
- View/download PDF
4. Impact of pre-biologic impairment on meeting domain-specific biologic responder definitions in patients with severe asthma
- Author
-
Perez-de-Llano, Luis, Scelo, Ghislaine, Canonica, G. Walter, Chen, Wenjia, Henley, William, Larenas-Linnemann, Désirée, Peters, Matthew J., Pfeffer, Paul E., Tran, Trung N., Ulrik, Charlotte Suppli, Popov, Todor A., Sadatsafavi, Mohsen, Hew, Mark, Máspero, Jorge, Gibson, Peter G., Christoff, George C., Fitzgerald, J. Mark, Torres-Duque, Carlos A., Porsbjerg, Celeste M., Papadopoulos, Nikolaos G., Papaioannou, Andriana I., Heffler, Enrico, Iwanaga, Takashi, Al-Ahmad, Mona, Kuna, Piotr, Fonseca, João A., Al-Lehebi, Riyad, Rhee, Chin Kook, Koh, Mariko Siyue, Cosio, Borja G., Perng (Steve), Diahn-Warng, Mahboub, Bassam, Menzies-Gow, Andrew N., Jackson, David J., Busby, John, Heaney, Liam G., Patel, Pujan H., Wang, Eileen, Wechsler, Michael E., Altraja, Alan, Lehtimäki, Lauri, Bourdin, Arnaud, Bjermer, Leif, Bulathsinhala, Lakmini, Carter, Victoria, Murray, Ruth, Beastall, Aaron, Denton, Eve, and Price, David B.
- Published
- 2024
- Full Text
- View/download PDF
5. Phenotyping of Severe Asthma in the Era of Broad-Acting Anti-Asthma Biologics
- Author
-
Bourdin, Arnaud, Brusselle, Guy, Couillard, Simon, Fajt, Merritt L., Heaney, Liam G., Israel, Elliot, McDowell, P. Jane, Menzies-Gow, Andrew, Martin, Neil, Mitchell, Patrick D., Petousi, Nayia, Quirce, Santiago, Schleich, Florence, and Pavord, Ian D.
- Published
- 2024
- Full Text
- View/download PDF
6. Anti–IL-4R versus anti–IL-5/5R after anti–IL-5/5R failure in asthma: An emulated target trial
- Author
-
Devouassoux, G., Taillé, C., Chanez, P., Bonniaud, P., Bourdin, A., Saint Raymond, C., Maurer, C., Beurnier, A., Roux, P., Margelidon, V., Boudjemaa, A., Mangiapan, G., Freymond, N., Didi, T., Russier, M., Garcia, G., Meyer, E. Popin, Dupin, C., Fouquet, F., Jouveshomme, S., Gaspard, W., Dury, S., Maillard, S. Habib, Izadifar, A., Cuvillon, E., Deslée, G., Barnig, C., Perotin, J.M., Gamez, A.S., Oster, J.P., Khayat, N., Chenivesse, C., Li, X., Appere de Vecchi, C., Gicquello, A., Rami, H., Vignal, G., Just, N., Blanc, X., Leroyer, C., Wemeau, L., Achkar, A., Sattler, C., Catherinot, E., Guilleminault, L., Gaillot-Drevon, M., Rochefort-Morel, C., Couturaud, F., Martin, P., Chabrol, A., Pegliasco, H., Sése, L., Romanet, S., Caverstri, B., Tcherakian, C., Magnan, A., Ahmed, E., Allibe, F., Beltramo, G., Michaux, K., Paleiron, N., Martinez, S., Begne, C., Tummino, C., Givel, C., Mourin, G., Salvator, H., Volpato, M., Drucbert, M., Rossignoli, N., Keddache, S., Justet, A., Andrejak, C., Valcke, J., Perrin, J., Mercy, M., Jouvenot, M., Soumagne, T., Elharrar, X., Douvry, B., Godbert, B., Maitre, B., Goyard, C., Didier, A., Cadet, E., Chabot, F., Gonzalez, J., Mattei, L., Gouitaa, M., Chauveau, S., Raymond, S., Dirou, S., Fry, S., Briault, A., Moui, A., Paris, A., NoelSavina, E., Olivier, C., Caradec, E., Roche, N., Picart, G., Belmont, L., Portel, L., Serra, M. Rocca, Guibert, N., Jean, R., Hadjadj, S., Guillo, S., Gauquelin, L., Estellat, C., Prigent, A., Larrousse, M., Jaffuel, D., Bourayou, Karima, Klising, Eve, Yelles, Nessima, Pochon, Sarra, Gouider, Amal, Medina, Hadj Kaci, Yasmine, Sellali, Djouher, Dahmani, Ndao, Diakhou, Vacher, Yannick, Achkar, Antoine, Ahmed, Engi, Alain, Didier, Allibe, Flora, Andrejak, Claire, De Vecchi, Corinne Appere, Barnig, Cindy, Begne, Camille, Belmont, Laure, Beltramo, Guillaume, Blanc, Xavier, Briault, Amandine, Cadet, Emmanuelle, Caradec, Emmanuela, Catherinot, Émilie, Cavestri, Beatrice, Chabrol, Alexandre, Chanez, Pascal, Chauveau, Simon, Couturaud, Francis, Cuvillon, Édouard, Deslee, Gaëtan, Didi, Toufik, Dirou, Stéphanie, Douvry, benoît, Drucbert, Mélanie, Dupin, Clairelyne, Dury, Sandra, Elharrar, Xavier, Fouquet, Helen, Freymond, Nathalie, Fry, Stéphanie, Gaillot-Drevon, Maud, Gamez, Anne Sophie, Garcia, Gilles, Gaspard, Wanda, Gicquello, Alice, Givel, Claire, Godbert, benoit, Gonzalez, Jésus, Gouitaa, Marion, Goupil, François, Goyard, Céline, Guibert, Nicolas, Guilleminault, Laurent, Habib-Maillard, Stéphanie, Hadjadj, Samra, Izadifar, Armine, Jean, Romain, Jouvenot, marie, Jouveshomme, Stéphane, Just, Nicolas, Justet, Aurélien, Keddache, Sophia, Khayath, Naji, Lemaire, Bertrand, Leroyer, Christophe, Li, Xing, Magnan, Antoine, Maitre, Bernard, Mangiapan, Gilles, Margelidon, Victor, Martin, Pascale, Martinez, Stéphanie, Mattei, Laura, Maurer, Cyril, Mercy, Magalie, Michaux, Karine, Moui, Antoine, Mourin, Gisèle, Noel-Savina, Elisa, Olivier, Cécile, Oster, Jean-Philippe, Paleiron, Nicolas, Paris, Audrey, Pegliasco, Hervé, Perotin Collard, Jeanne-Marie, Perrin, Julie, Picart, Gaël, Pison, Christophe, Popin-Meyer, Élisabeth, Portel, Laurent, Rami, Hassina, Raymond, Stéphane, Serra, Mireille Rocca, Rochefort-Morel, Cécile, Romanet, Stéphanie, Rossignoli, Nadine, Roux, Pauline, Russier, Maud, Saint-Raymond, Christel, Salmeron, Sergio, Salvator, Helene, Sattler, Caroline, Sese, Lucile, Soumagne, Thibaud, Tcherakian, Colas, Tiotiu, Angélica, Tummino, Céline, Valcke-Brossollet, Judith, Vignal, Guillaume, Volpato, Mathilde, Wemeau, Lidwine, Valery, Solène, Simon-Tillaux, Noémie, Devouassoux, Gilles, Bonniaud, Philippe, Beurnier, Antoine, Boudjemaa, Amel, Chenivesse, Cécile, Bourdin, Arnaud, Gauquelin, Lisa, Guillo, Sylvie, Taillé, Camille, and Estellat, Candice
- Published
- 2024
- Full Text
- View/download PDF
7. Analysis of comorbidities and multimorbidity in adult patients in the International Severe Asthma Registry
- Author
-
Scelo, Ghislaine, Torres-Duque, Carlos A., Maspero, Jorge, Tran, Trung N., Murray, Ruth, Martin, Neil, Menzies-Gow, Andrew N., Hew, Mark, Peters, Matthew J., Gibson, Peter G., Christoff, George C., Popov, Todor A., Côté, Andréanne, Bergeron, Celine, Dorscheid, Delbert, FitzGerald, J. Mark, Chapman, Kenneth R., Boulet, Louis Philippe, Bhutani, Mohit, Sadatsafavi, Mohsen, Jiménez-Maldonado, Libardo, Duran-Silva, Mauricio, Rodriguez, Bellanid, Celis-Preciado, Carlos Andres, Cano-Rosales, Diana Jimena, Solarte, Ivan, Fernandez-Sanchez, Maria Jose, Parada-Tovar, Patricia, von Bülow, Anna, Bjerrum, Anne Sofie, Ulrik, Charlotte S., Assing, Karin Dahl, Rasmussen, Linda Makowska, Hansen, Susanne, Altraja, Alan, Bourdin, Arnaud, Taille, Camille, Charriot, Jeremy, Roche, Nicolas, Papaioannou, Andriana I., Kostikas, Konstantinos, Papadopoulos, Nikolaos G., Salvi, Sundeep, Long, Deirdre, Mitchell, Patrick D., Costello, Richard, Sirena, Concetta, Cardini, Cristina, Heffler, Enrico, Puggioni, Francesca, Canonica, Giorgio Walter, Guida, Giuseppe, Iwanaga, Takashi, Al-Ahmad, Mona, Linnemann, Désirée Larenas, Garcia, Ulises, Kuna, Piotr, Fonseca, João A., Al-Lehebi, Riyad, Koh, Mariko Siyue, Rhee, Chin Kook, Cosio, Borja G., de Llano, Luis Perez, Perng (Steve), Diahn-Warng, Huang, Erick Wan-Chun, Wang, Hao-Chien, Tsai, Ming-Ju, Mahboub, Bassam, Salameh, Laila Ibraheem Jaber, Jackson, David, Busby, John, Heaney, Liam G., Pfeffer, Paul, Goddard, Amanda Grippen, Wang, Eileen, Hoyte, Flavia, Wechsler, Michael E., Chapman, Nicholas, Katial, Rohit, Carter, Victoria, Bulathsinhala, Lakmini, Eleangovan, Neva, Ariti, Con, Lyu, Juntao, Price, David B., and Porsbjerg, Celeste
- Published
- 2024
- Full Text
- View/download PDF
8. Anti-IL-4R versus Anti-IL-5/5R after Anti-IL-5/5R failure in asthma: an emulated target trial
- Author
-
Valery, Solène, primary, Simon-Tillaux, Noémie, additional, Devouassoux, Gilles, additional, Bonniaud, Philippe, additional, Beurnier, Antoine, additional, Boudjemaa, Amel, additional, Chenivesse, Cécile, additional, Bourdin, Arnaud, additional, Gauquelin, Lisa, additional, Guillo, Sylvie, additional, Taillé, Camille, additional, Estellat, Candice, additional, Devouassoux, G., additional, Taillé, C., additional, Chanez, P., additional, Bonniaud, P., additional, Bourdin, A., additional, Raymond, C.Saint, additional, Maurer, C., additional, Beurnier, A., additional, Roux, P., additional, Margelidon, V., additional, Boudjemaa, A., additional, Mangiapan, G., additional, Freymond, N., additional, Didi, T., additional, Russier, M., additional, Garcia, G., additional, Meyer, E.Popin, additional, Dupin, C., additional, Fouquet, F., additional, Jouveshomme, S., additional, Gaspard, W., additional, Dury, S., additional, Maillard, S.Habib, additional, Izadifar, A., additional, Cuvillon, E., additional, Deslée, G., additional, Barnig, C., additional, Perotin, J.M., additional, Gamez, A.S., additional, Oster, J.P., additional, Khayat, N., additional, Chenivesse, C., additional, Li, X., additional, de Vecchi, C.Appere, additional, Gicquello, A., additional, Rami, H., additional, Vignal, G., additional, Just, N., additional, Blanc, X., additional, Leroyer, C., additional, Wemeau, L., additional, Achkar, A., additional, Sattler, C., additional, Catherinot, E., additional, Guilleminault, L., additional, Gaillot-Drevon, M., additional, Rochefort-Morel, C., additional, Couturaud, F., additional, Martin, P., additional, Chabrol, A., additional, Pegliasco, H., additional, Sése, L., additional, Romanet, S., additional, Caverstri, B., additional, Tcherakian, C., additional, Magnan, A., additional, Ahmed, E., additional, Allibe, F., additional, Beltramo, G., additional, Michaux, K., additional, Paleiron, N., additional, Martinez, S., additional, Begne, C., additional, Tummino, C., additional, Givel, C., additional, Mourin, G., additional, Salvator, H., additional, Volpato, M., additional, Drucbert, M., additional, Rossignoli, N., additional, Keddache, S., additional, Justet, A., additional, Andrejak, C., additional, Valcke, J., additional, Perrin, J., additional, Mercy, M., additional, Jouvenot, M., additional, Soumagne, T., additional, Elharrar, X., additional, Douvry, B., additional, Godbert, B., additional, Maitre, B., additional, Goyard, C., additional, Didier, A., additional, Cadet, E., additional, Chabot, F., additional, Gonzalez, J., additional, Mattei, L., additional, Gouitaa, M., additional, Chauveau, S., additional, Raymond, S., additional, Dirou, S., additional, Fry, S., additional, Briault, A., additional, Moui, A., additional, Paris, A., additional, NoelSavina, E., additional, Olivier, C., additional, Caradec, E., additional, Roche, N., additional, Picart, G., additional, Belmont, L., additional, Portel, L., additional, Serra, M.Rocca, additional, Guibert, N., additional, Jean, R., additional, Hadjadj, S., additional, Guillo, S., additional, Gauquelin, L., additional, Estellat, C., additional, Prigent, A., additional, Larrousse, M., additional, and Jaffuel, D., additional
- Published
- 2024
- Full Text
- View/download PDF
9. VJBM-2023-0014 Final
- Author
-
Corren, Jonathan, primary, Wechsler, Michael, additional, Colice, Gene, additional, Bowen, Karin, additional, Menzies-Gow, Andrew, additional, Israel, Elliot, additional, Griffiths, Janet, additional, Almqvist, Gun, additional, Ponnarambil, Sandhia, additional, Brightling, Christopher, additional, and Bourdin, Arnaud, additional
- Published
- 2024
- Full Text
- View/download PDF
10. Hospitalizations for Chronic Obstructive Pulmonary Disease Exacerbation During COVID-19
- Author
-
Bourdin, Arnaud, primary, Ahmed, Engi, additional, Vachier, Isabelle, additional, Roche, Nicolas, additional, Pissarra, Joana, additional, Malafaye, Nicolas, additional, and Molinari, Nicolas, additional
- Published
- 2024
- Full Text
- View/download PDF
11. Altered skeletal muscle function and beneficial effects of exercise training in a rat model of induced pulmonary emphysema
- Author
-
Passerieux, Emilie, primary, Desplanche, Elodie, additional, Alburquerque, Laurie, additional, Wynands, Quentin, additional, Bellanger, Axel, additional, Virsolvy, Anne, additional, Gouzi, Farés, additional, Cazorla, Olivier, additional, Bourdin, Arnaud, additional, Hayot, Maurice, additional, and Pomiès, Pascal, additional
- Published
- 2024
- Full Text
- View/download PDF
12. The HHIP gene: from a candidate to an established participant in COPD susceptibility
- Author
-
Lahmar, Zakaria, primary, Bergougnoux, Anne, additional, and Bourdin, Arnaud, additional
- Published
- 2024
- Full Text
- View/download PDF
13. Transition of care from adolescence to early adulthood in severe asthmatic patients treated with omalizumab in real life.
- Author
-
Taillé, Camille, Humbert, Marc, Bourdin, Arnaud, Thonnelier, Céline, Lajoinie, Audrey, Chassetuillier, Jules, Molimard, Mathieu, and Deschildre, Antoine
- Published
- 2024
- Full Text
- View/download PDF
14. Trends in Systemic Glucocorticoid Utilization in the United Kingdom from 1990 to 2019: A Population-Based, Serial Cross-Sectional Analysis
- Author
-
Menzies-Gow, Andrew, primary, Tran, Trung, additional, Stanley, Brooklyn, additional, Carter, Victoria, additional, Smolen, Josef, additional, Bourdin, Arnaud, additional, Fitzgerald, J, additional, Raine, Tim, additional, Chapaneri, Jatin, additional, Emmanuel, Benjamin, additional, Jackson, David, additional, and Price, David, additional
- Published
- 2024
- Full Text
- View/download PDF
15. Severe asthma care trajectories: the French RAMSES cohort
- Author
-
Perotin, Jeanne-Marie, primary, Gauquelin, Lisa, additional, Just, Nicolas, additional, Devouassoux, Gilles, additional, Chenivesse, Cécile, additional, Bourdin, Arnaud, additional, Garcia, Gilles, additional, Raymond, Christel Saint, additional, Boudjemaa, Amel, additional, Bonniaud, Philippe, additional, Chanez, Pascal, additional, Barnig, Cindy, additional, Beurnier, Antoine, additional, Maurer, Cyril, additional, Freymond, Nathalie, additional, Didi, Toufik, additional, Tcherakian, Colas, additional, Russier, Maud, additional, Drucbert, Mélanie, additional, Guillo, Sylvie, additional, Estellat, Candice, additional, and Taillé, Camille, additional
- Published
- 2024
- Full Text
- View/download PDF
16. Evaluating the Effect of Dupilumab on Type 2 Airway Inflammation and Mucus Plugging in Patients with Uncontrolled Moderate-To-Severe Asthma: the VESTIGE Trial
- Author
-
Castro, Mario, primary, Papi, Alberto, additional, Porsbjerg, Celeste, additional, Lugogo, Njira, additional, Brightling, Christopher, additional, González-Barcala, Francisco-Javier, additional, Bourdin, Arnaud, additional, Ostrovskyy, Mykola, additional, Staevska, Maria, additional, Chou, Pai-Chen, additional, Duca, Liliana, additional, Pereria, Ana, additional, Fogarty, Charles, additional, Nadama, Rufai, additional, Zhang, Mei, additional, Rodrigues, Amelie, additional, Soler, Xavier, additional, Pantelimon, Simona, additional, Sacks, Harry, additional, Deniz, Yamo, additional, Rowe, Paul, additional, De Prado Gomez, Lucia, additional, and Jacob-Nara, Juby, additional
- Published
- 2024
- Full Text
- View/download PDF
17. Longitudinal patterns of intermittent oral corticosteroid use for asthma in the UK
- Author
-
Tran, Trung N., primary, Heatley, Heath, additional, Rowell, Jennifer, additional, Kai Chan, Jeffrey Shi, additional, Bourdin, Arnaud, additional, Chapaneri, Jatin, additional, Emmanuel, Benjamin, additional, Gibson, Danny, additional, Jackson, David J., additional, Menzies-Gow, Andrew N., additional, Murray, Ruth, additional, Skinner, Derek, additional, and Price, David, additional
- Published
- 2024
- Full Text
- View/download PDF
18. Reply to “Exploring the long-term effects of biologic initiation in severe asthma: Insights from the International Severe Asthma Registry”
- Author
-
Chen, Wenjia, primary, Tran, Trung N., additional, Sadatsafavi, Mohsen, additional, Murray, Ruth B., additional, Boon Wong, Nigel Chong, additional, Ali, Nasloon, additional, Ariti, Con, additional, Bulathsinhala, Lakmini, additional, Garcia Gil, Esther, additional, FitzGerald, J. Mark, additional, Alacqua, Marianna, additional, Al-Ahmad, Mona, additional, Altraja, Alan, additional, Al-Lehebi, Riyad, additional, Bhutani, Mohit, additional, Bjermer, Leif, additional, Bjerrum, Anne-Sofie, additional, Bourdin, Arnaud, additional, von Bülow, Anna, additional, Busby, John, additional, Canonica, Giorgio Walter, additional, Carter, Victoria, additional, Christoff, George C., additional, Cosio, Borja G., additional, Costello, Richard W., additional, Fonseca, João A., additional, Gibson, Peter G., additional, Yoo, Kwang Ha, additional, Heaney, Liam G., additional, Heffler, Enrico, additional, Hew, Mark, additional, Hilberg, Ole, additional, Hoyte, Flavia, additional, Iwanaga, Takashi, additional, Jackson, David J., additional, Jones, Rupert C., additional, Koh, Mariko Siyue, additional, Kuna, Piotr, additional, Larenas-Linnemann, Désirée, additional, Lehmann, Sverre, additional, Lehtimäki, Lauri, additional, Lyu, Juntao, additional, Mahboub, Bassam, additional, Maspero, Jorge, additional, Menzies-Gow, Andrew N., additional, Newell, Anthony, additional, Sirena, Concetta, additional, Papadopoulos, Nikolaos G., additional, Papaioannou, Andriana I., additional, Perez-de-Llano, Luis, additional, Perng (Steve), Diahn-Warng, additional, Peters, Matthew J., additional, Pfeffer, Paul E., additional, Porsbjerg, Celeste M., additional, Popov, Todor A., additional, Rhee, Chin Kook, additional, Salvi, Sundeep, additional, Taillé, Camille, additional, Taube, Christian, additional, Torres-Duque, Carlos A., additional, Ulrik, Charlotte, additional, Ra, Seung Won, additional, Wang, Eileen, additional, Wechsler, Michael E., additional, and Price, David B., additional
- Published
- 2024
- Full Text
- View/download PDF
19. Long-Term Efficacy Of Dupilumab In Patients With Moderate-To-Severe Type 2 Asthma Stratified By Baseline Characteristics During The 96-Week TRAVERSE Study
- Author
-
Wechsler, Michael, primary, Rogers, Linda, additional, Canonica, Giorgio, additional, Bourdin, Arnaud, additional, Altincatal, Arman, additional, Hardin, Megan, additional, Soler, Xavier, additional, Rowe, Paul, additional, Deniz, Yamo, additional, Sacks, Harry, additional, and Jacob-Nara, Juby, additional
- Published
- 2024
- Full Text
- View/download PDF
20. Efficacy and Safety of Benralizumab Compared with Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Patients Receiving Standard of Care Therapy: Phase 3 MANDARA Study
- Author
-
Wechsler, Michael, primary, Nair, Parameswaran, additional, Terrier, Benjamin, additional, Walz, Bastian, additional, Bourdin, Arnaud, additional, Jayne, David, additional, Jackson, David, additional, Roufosse, Florence, additional, Sjö, Lena Börjesson, additional, Fan, Ying, additional, Jison, Maria, additional, McCrae, Christopher, additional, Necander, Sofia, additional, Shavit, Anat, additional, Walton, Claire, additional, and Merkel, Peter, additional
- Published
- 2024
- Full Text
- View/download PDF
21. CT Imaging Assessment of Response to Treatment in Allergic Bronchopulmonary Aspergillosis in Adults With Bronchial Asthma
- Author
-
Godet, Cendrine, primary, Brun, Anne-Laure, additional, Couturaud, Francis, additional, Laurent, François, additional, Frat, Jean-Pierre, additional, Marchand-Adam, Sylvain, additional, Gagnadoux, Frédéric, additional, Blanchard, Elodie, additional, Taillé, Camille, additional, Philippe, Bruno, additional, Hirschi, Sandrine, additional, Andréjak, Claire, additional, Bourdin, Arnaud, additional, Chenivesse, Cécile, additional, Dominique, Stéphane, additional, Mangiapan, Gilles, additional, Murris-Espin, Marlène, additional, Rivière, Frédéric, additional, Garcia, Gilles, additional, Blanc, François-Xavier, additional, Goupil, François, additional, Bergeron, Anne, additional, Flament, Thomas, additional, Priou, Pascaline, additional, Mal, Hervé, additional, de Keizer, Joe, additional, Ragot, Stéphanie, additional, Cadranel, Jacques, additional, Le Guen, Pierre, additional, Dupin, Clairelyne, additional, Meurice, Jean Claude, additional, Verdaguer, Marion, additional, Delétage-Métreau, Céline, additional, Le Mao, Raphael, additional, Tromer, Cécile, additional, Fajole, Gaëlle, additional, Rayez, Mélanie, additional, Raymond, Christel Saint, additional, Gheerbrant, Hubert, additional, Badatcheff, Anne, additional, Person, Christine, additional, Macey, Julie, additional, Dermant, Xavier, additional, Boitiaux, Jean-François, additional, Gosset-Woimant, Marine, additional, Metz-Favre, Carine, additional, Degot, Tristan, additional, Poulet, Claire, additional, Popin, Elisabeth, additional, Gamez, Anne Sophie, additional, Boissin, Clément, additional, Prevotat, Anne, additional, Brouquières, Danielle, additional, Le Floch, Hervé, additional, Morisse-Pradier, Hélène, additional, Sattler, Caroline, additional, Muti, Daniela, additional, Germaud, Patrick, additional, Dirou, Stéphanie, additional, Paris, Audrey, additional, Melloni, Boris, additional, Ballouhey, Julia, additional, Bondeelle, Louise, additional, Laurent, Lucie, additional, Belleguic, Chantal, additional, Kerjouan, Mallorie, additional, Deslée, Gaëtan, additional, Dury, Sandra, additional, Bergot, Emmanuel, additional, Magnier, Romain, additional, Morel, Hugues, additional, Lemaire, Bertrand, additional, Tumino, Cécile, additional, Sénéchal, Agathe, additional, Choinier, Pascaline, additional, and Parrot, Antoine, additional
- Published
- 2024
- Full Text
- View/download PDF
22. Early and late effects of volatile sedation with sevoflurane on respiratory mechanics of critically ill COPD patients.
- Author
-
Jung, Boris, Fosset, Maxime, Amalric, Matthieu, Baedorf-Kassis, Elias, O'Gara, Brian, Sarge, Todd, Moulaire, Valerie, Brunot, Vincent, Bourdin, Arnaud, Molinari, Nicolas, and Matecki, Stefan
- Subjects
OBSTRUCTIVE lung disease treatment ,BLOOD gases analysis ,SEVOFLURANE ,RESEARCH funding ,CRITICALLY ill ,PATIENTS ,ACADEMIC medical centers ,POSITIVE end-expiratory pressure ,INHALATION anesthesia ,STATISTICAL sampling ,TREATMENT effectiveness ,RANDOMIZED controlled trials ,DESCRIPTIVE statistics ,PROPOFOL ,ARTIFICIAL respiration ,INTRAVENOUS anesthesia ,RESPIRATORY measurements ,AIRWAY (Anatomy) ,RESPIRATORY mechanics ,CRITICAL care medicine - Abstract
Background: The objective was to compare sevoflurane, a volatile sedation agent with potential bronchodilatory properties, with propofol on respiratory mechanics in critically ill patients with COPD exacerbation. Methods: Prospective study in an ICU enrolling critically ill intubated patients with severe COPD exacerbation and comparing propofol and sevoflurane after 1:1 randomisation. Respiratory system mechanics (airway resistance, PEEPi, trapped volume, ventilatory ratio and respiratory system compliance), gas exchange, vitals, safety and outcome were measured at inclusion and then until H48. Total airway resistance change from baseline to H48 in both sevoflurane and propofol groups was the main endpoint. Results: Sixteen patients were enrolled and were sedated for 126 h(61–228) in the propofol group and 207 h(171–216) in the sevoflurane group. At baseline, airway resistance was 21.6cmH2O/l/s(19.8–21.6) in the propofol group and 20.4cmH2O/l/s(18.6–26.4) in the sevoflurane group, (p = 0.73); trapped volume was 260 ml(176–290) in the propofol group and 73 ml(35–126) in the sevoflurane group, p = 0.02. Intrinsic PEEP was 1.5cmH2O(1–3) in both groups after external PEEP optimization. There was neither early (H4) or late (H48) significant difference in airway resistance and respiratory mechanics parameters between the two groups. Conclusions: In critically ill patients intubated with COPD exacerbation, there was no significant difference in respiratory mechanics between sevoflurane and propofol from inclusion to H4 and H48. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
23. Healthcare Resource Utilization Associated with Intermittent Oral Corticosteroid Prescribing Patterns in Asthma.
- Author
-
Tran, Trung N, Heatley, Heath, Bourdin, Arnaud, Menzies-Gow, Andrew, Jackson, David J, Maslova, Ekaterina, Chapaneri, Jatin, Henley, William, Carter, Victoria, Chan, Jeffrey Shi Kai, Ariti, Cono, Haughney, John, and Price, David
- Subjects
LENGTH of stay in hospitals ,HOSPITAL statistics ,MEDICAL care costs ,MEDICAL records ,PRIMARY care - Abstract
Purpose: Oral corticosteroid (OCS) use for asthma is associated with considerable healthcare resource utilization (HCRU) and costs. However, no study has investigated this in relation to patterns of intermittent OCS prescription. Methods: This historical UK cohort study used primary care medical records, linked to Hospital Episode Statistics, from 2008 to 2019, of patients (≥ 4 years old) with asthma prescribed intermittent OCS. Patients were categorized by OCS prescribing pattern (one-off [single], less frequent [≥ 90-day gap] and frequent [< 90-day gap]) and matched 1:1 (by sex, age and index date) with people never prescribed OCS with/without asthma. HCRU (reported as episodes, except for length of hospital stay [days] and any prescription [records]) and associated costs were compared between intermittent OCS and non-OCS cohorts, and among intermittent OCS prescribing patterns. Results: Of 149,191 eligible patients, 50.3% had one-off, 27.4% less frequent, and 22.3% frequent intermittent OCS prescribing patterns. Annualized non-respiratory HCRU rates were greater in the intermittent OCS versus non-OCS cohorts for GP visits (5.93 vs 4.70 episodes, p < 0.0001), hospital admissions (0.24 vs 0.16 episodes, p < 0.0001), and length of stay (1.87 vs 1.58 days, p < 0.0001). In the intermittent OCS cohort, rates were highest in the frequent prescribing group for GP visits (7.49 episodes; p < 0.0001 vs one-off), length of stay (2.15 days; p < 0.0001) and any prescription including OCS (25.22 prescriptions; p < 0.0001). Mean per-patient non-respiratory related and all-cause HCRU-related costs were higher with intermittent OCS than no OCS (£ 3902 vs £ 2722 and £ 8623 vs £ 4929, respectively), as were mean annualized costs (£ 565 vs £ 313 and £ 1526 vs £ 634, respectively). A dose–response relationship existed; HCRU-related costs were highest in the frequent prescribing cohort (p < 0.0001). Conclusion: Intermittent OCS use and more frequent intermittent OCS prescription patterns were associated with increased HCRU and associated costs. Improved asthma management is needed to reduce reliance on intermittent OCS in primary care. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
24. Liver disease in germline mutations of telomere-related genes: Prevalence, clinical, radiological, pathological features, outcome, and risk factors.
- Author
-
Sidali, Sabrina, Borie, Raphaël, de Fontbrune, Flore Sicre, El Husseini, Kinan, Rautou, Pierre-Emmanuel, Lainey, Elodie, Goria, Odile, Crestani, Bruno, Cadranel, Jacques, Cottin, Vincent, Bunel, Vincent, Dumortier, Jérôme, Jacquemin, Emmanuel, Reboux, Noémi, Hirschi, Sandrine, Bourdin, Arnaud, Meszaros, Magdalena, Dharancy, Sebastien, Hilaire, Sophie, and Mallet, Vincent
- Published
- 2024
- Full Text
- View/download PDF
25. Prevalence of anti-neutrophil cytoplasmic antibody-associated vasculitis in the south of France, using the capture-recapture method.
- Author
-
Rubenstein, Emma, Henneton, Pierrick, Rivière, Sophie, Casanova, Marie-Laure, Broner, Jonathan, Arnaud, Erik, Oziol, Eric, Quintrec, Moglie Le, Moranne, Olivier, Jorgensen, Christian, Combe, Bernard, Bourdin, Arnaud, Fontaine, Christophe, Schiffmann, Aurélie, Fraison, Jean-Baptiste, Hallé, Olivier, Fraisse, Thibaut, Veysseyre, Frederic, Taieb, Guillaume, and Aerts, Cécile
- Subjects
VASCULITIS ,CROSS-sectional method ,RESEARCH funding ,ANTINEUTROPHIL cytoplasmic antibodies ,CONFIDENCE intervals - Abstract
Objectives This study aimed to estimate the prevalence of ANCA-associated vasculitis (AAV). That is, granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA), in Southern France in 2018, and evaluate differences among Europeans and non-Europeans. Methods This population-based, cross-sectional study used four sources (hospitals, community-based physicians, laboratories, National Health Insurance) to identify adults ≥15 years diagnosed with GPA, MPA or EGPA, living in Hérault and Gard in 2018. Cases were defined using the ACR/EULAR classification criteria, and if necessary, the European Medicines Agency algorithm. Prevalence estimates were standardised to the world population and capture-recapture analysis was used to assess the comprehensiveness of the estimation. The influence of geographical origin was evaluated. Results A total of 202 patients were selected, with 86 cases of GPA (42.6%), 85 cases of MPA (42.1%) and 31 cases of EGPA (15.3%). The standardised prevalence estimates per million inhabitants for 2018 were: 103 (95%CI 84–125) for AAV, 48 (95%CI 35–64) for GPA, 39 (95%CI 28–53) for MPA and 16 (95%CI 9–26) for EGPA, 36 (95%CI 25–50) for anti-PR3 positive AAV, 46 (95%CI 34–61) for anti-MPO positive AAV, and 16 (95%CI 9–26) for ANCA-negative AAV. The global estimation of comprehensiveness by capture-recapture analysis was 80.5%. The number of AAV cases was higher for non-European residents (P = 0.001), particularly for MPA (P < 0.0001). Conclusion We provide a new estimate of AAV prevalence in France and show a higher prevalence of MPA in non-European patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
26. Similarities and differences of interstitial lung disease associated with pathogenic variants in SFTPC and ABCA3 in adults.
- Author
-
Diesler, Rémi, Legendre, Marie, Si‐Mohamed, Salim, Brillet, Pierre‐Yves, Wemeau, Lidwine, Manali, Effrosyni D., Gagnadoux, Frédéric, Hirschi, Sandrine, Lorillon, Gwenaël, Reynaud‐Gaubert, Martine, Bironneau, Vanessa, Blanchard, Elodie, Bourdin, Arnaud, Dominique, Stéphane, Justet, Aurélien, Macey, Julie, Marchand‐Adam, Sylvain, Morisse‐Pradier, Hélène, Nunes, Hilario, and Papiris, Spyros A.
- Subjects
INTERSTITIAL lung diseases ,IDIOPATHIC pulmonary fibrosis ,PULMONARY fibrosis ,ADULTS ,COMPUTED tomography ,LUNG transplantation - Abstract
Background and Objective: Variants in surfactant genes SFTPC or ABCA3 are responsible for interstitial lung disease (ILD) in children and adults, with few studies in adults. Methods: We conducted a multicentre retrospective study of all consecutive adult patients diagnosed with ILD associated with variants in SFTPC or ABCA3 in the French rare pulmonary diseases network, OrphaLung. Variants and chest computed tomography (CT) features were centrally reviewed. Results: We included 36 patients (median age: 34 years, 20 males), 22 in the SFTPC group and 14 in the ABCA3 group. Clinical characteristics were similar between groups. Baseline median FVC was 59% ([52–72]) and DLco was 44% ([35–50]). An unclassifiable pattern of fibrosing ILD was the most frequent on chest CT, found in 85% of patients, however with a distinct phenotype with ground‐glass opacities and/or cysts. Nonspecific interstitial pneumonia and usual interstitial pneumonia were the most common histological patterns in the ABCA3 group and in the SFTPC group, respectively. Annually, FVC and DLCO declined by 1.87% and 2.43% in the SFTPC group, respectively, and by 0.72% and 0.95% in the ABCA3 group, respectively (FVC, p = 0.014 and DLCO, p = 0.004 for comparison between groups). Median time to death or lung transplantation was 10 years in the SFTPC group and was not reached at the end of follow‐up in the ABCA3 group. Conclusion: SFTPC and ABCA3‐associated ILD present with a distinct phenotype and prognosis. A radiologic pattern of fibrosing ILD with ground‐glass opacities and/or cysts is frequently found in these rare conditions. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
27. Outcomes and risk assessment in pulmonary veno-occlusive disease.
- Author
-
Boucly, Athénaïs, Solinas, Sabina, Beurnier, Antoine, Jaïs, Xavier, Keddache, Sophia, Eyries, Mélanie, Seferian, Andrei, Jevnikar, Mitja, Roche, Anne, Bulifon, Sophie, Bourdin, Arnaud, Chaouat, Ari, Cottin, Vincent, Bertoletti, Laurent, Savale, Laurent, Humbert, Marc, Sitbon, Olivier, and Montani, David
- Published
- 2024
- Full Text
- View/download PDF
28. Infections in autoimmune pulmonary alveolar proteinosis: a large retrospective cohort.
- Author
-
Mabo, Axelle, Borie, Raphael, Wemeau-Stervinou, Lidwine, Uzunhan, Yurdagül, Gomez, Emmanuel, Prevot, Gregoire, Reynaud-Gaubert, Martine, Traclet, Julie, Bergot, Emmanuel, Cadranel, Jacques, Marchand-Adam, Sylvain, Bergeron, Anne, Blanchard, Elodie, Bondue, Benjamin, Bonniaud, Philippe, Bourdin, Arnaud, Burgel, Pierre Regis, Hirschi, Sandrine, Marquette, Charles Hugo, and Quétant, Sébastien
- Subjects
PULMONARY alveolar proteinosis ,LUNG infections - Published
- 2024
- Full Text
- View/download PDF
29. Longitudinal patterns of intermittent oral corticosteroid therapy for asthma in the United Kingdom
- Author
-
Tran, Trung N., Heatley, Heath, Rowell, Jennifer, Chan, Jeffrey Shi Kai, Bourdin, Arnaud, Chapaneri, Jatin, Emmanuel, Benjamin, Gibson, Danny, Jackson, David J., Menzies-Gow, Andrew N., Murray, Ruth, Skinner, Derek, and Price, David B.
- Published
- 2024
- Full Text
- View/download PDF
30. Generation of a healthy heavy smoker patient-derived induced pluripotent stem cell line UHOMi007-A from peripheral blood mononuclear cells
- Author
-
Ahmed, Engi, Fieldès, Mathieu, Bourguignon, Chloé, Mianné, Joffrey, Petit, Aurélie, Amel, Nasri, Foisset, Florent, Bourdais, Carine, Vachier, Isabelle, Assou, Said, De Vos, John, and Bourdin, Arnaud
- Published
- 2024
- Full Text
- View/download PDF
31. Effect of tezepelumab on healthcare utilization in patients with severe, uncontrolled asthma
- Author
-
Menzies-Gow, Andrew, Bourdin, Arnaud, Chupp, Geoffrey, Israel, Elliot, Hellqvist, Åsa, Hunter, Gillian, Roseti, Stephanie L., Ambrose, Christopher S., Llanos, Jean-Pierre, Cook, Bill, Corren, Jonathan, and Colice, Gene
- Abstract
Tezepelumab, a human monoclonal antibody, blocks thymic stromal lymphopoietin. In the phase 3 NAVIGATOR study, tezepelumab reduced exacerbations and improved lung function, asthma control, and health-related quality of life compared with placebo in patients with severe, uncontrolled asthma. However, little is known about the impact of tezepelumab on healthcare utilization (HCU) in these patients.
- Published
- 2024
- Full Text
- View/download PDF
32. Real‐world biologics response and super‐response in the International Severe Asthma Registry cohort.
- Author
-
Denton, Eve, Hew, Mark, Peters, Matthew J., Upham, John W., Bulathsinhala, Lakmini, Tran, Trung N., Martin, Neil, Bergeron, Celine, Al‐Ahmad, Mona, Altraja, Alan, Larenas‐Linnemann, Désirée, Murray, Ruth, Celis‐Preciado, Carlos Andrés, Al‐Lehebi, Riyad, Belhassen, Manon, Bhutani, Mohit, Bosnic‐Anticevich, Sinthia Z., Bourdin, Arnaud, Brusselle, Guy G., and Busby, John
- Subjects
- *
FORCED expiratory volume , *ASTHMA , *BIOLOGICALS , *ASTHMATICS , *BIOTHERAPY - Abstract
Background Methods Results Conclusions Biologic asthma therapies reduce exacerbations and long‐term oral corticosteroids (LTOCS) use in randomized controlled trials (RCTs); however, there are limited data on outcomes among patients ineligible for RCTs. Hence, we investigated responsiveness to biologics in a real‐world population of adults with severe asthma.Adults in the International Severe Asthma Registry (ISAR) with ≥24 weeks of follow‐up were grouped into those who did, or did not, initiate biologics (anti‐IgE, anti‐IL5/IL5R, anti‐IL4/13). Treatment responses were examined across four domains: forced expiratory volume in 1 second (FEV1) increase by ≥100 mL, improved asthma control, annualized exacerbation rate (AER) reduction ≥50%, and any LTOCS dose reduction. Super‐response criteria were: FEV1 increase by ≥500 mL, new well‐controlled asthma, no exacerbations, and LTOCS cessation or tapering to ≤5 mg/day.5.3% of ISAR patients met basic RCT inclusion criteria; 2116/8451 started biologics. Biologic initiators had worse baseline impairment than non‐initiators, despite having similar biomarker levels. Half or more of initiators had treatment responses: 59% AER reduction, 54% FEV1 increase, 49% improved control, 49% reduced LTOCS, of which 32%, 19%, 30%, and 39%, respectively, were super‐responses. Responses/super‐responses were more frequent in biologic initiators than in non‐initiators; nevertheless, ~40–50% of initiators did not meet response criteria.Most patients with severe asthma are ineligible for RCTs of biologic therapies. Biologics are initiated in patients who have worse baseline impairments than non‐initiators despite similar biomarker levels. Although biologic initiators exhibited clinical responses and super‐responses in all outcome domains, 40–50% did not meet the response criteria. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
33. Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis.
- Author
-
Wechsler, Michael E., Nair, Parameswaran, Terrier, Benjamin, Walz, Bastian, Bourdin, Arnaud, Jayne, David R. W., Jackson, David J., Roufosse, Florence, Sjö, Lena Börjesson, Ying Fan, Jison, Maria, McCrae, Christopher, Necander, Sofia, Shavit, Anat, Walton, Claire, and Merkel, Peter A.
- Abstract
BACKGROUND Eosinophilic granulomatosis with polyangiitis (EGPA) is a vasculitis characterized by eosinophilic inflammation. Benralizumab, a monoclonal antibody against the interleukin-5α receptor expressed on eosinophils, may be an option for treating EGPA. METHODS We conducted a multicenter, double-blind, phase 3, randomized, active-controlled noninferiority trial to evaluate the efficacy and safety of benralizumab as compared with mepolizumab. Adults with relapsing or refractory EGPA who were receiving standard care were randomly assigned in a 1:1 ratio to receive benralizumab (30 mg) or mepolizumab (300 mg) subcutaneously every 4 weeks for 52 weeks. The primary end point was remission at weeks 36 and 48 (prespecifled noninferiority margin, -25 percentage points). Secondary end points included the accrued duration of remission, time to first relapse, oral glucocorticoid use, eosinophil count, and safety. RESULTS A total of 140 patients underwent randomization (70 assigned to each group). The adjusted percentage of patients with remission at weeks 36 and 48 was 59% in the benralizumab group and 56% in the mepolizumab group (difference, 3 percentage points; 95% confidence interval [CI], -13 to 18; P=0.73 for superiority), showing noninferiority but not superiority of benralizumab to mepolizumab. The accrued duration of remission and the time to first relapse were similar in the two groups. Complete withdrawal of oral glucocorticoids during weeks 48 through 52 was achieved in 41% of the patients who received benralizumab and 26% of those who received mepolizumab. The mean (±SD) blood eosinophil count at baseline was 306.0±225.0 per microliter in the benralizumab group and 384.9±563.6 per micro-liter in the mepolizumab group, decreasing to 32.4±40.8 and 71.8±54.4 per micro-liter, respectively, at week 52. Adverse events were reported in 90% of the patients in the benralizumab group and 96% of those in the mepolizumab group; serious adverse events were reported in 6% and 13%, respectively. CONCLUSIONS Benralizumab was noninferior to mepolizumab for the induction of remission in patients with relapsing or refractory EGPA. (Funded by AstraZeneca; MANDARA ClinicalTrials.gov number, NCT04157348.) [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
34. Imagining the severe asthma decision trees of the future.
- Author
-
Bourdin A, Bardin P, and Chanez P
- Abstract
Introduction: There are no validated decision-making algorithms concerning severe asthma (SA) management. Future risks are crucial factors and can be derived from SA trajectories., Areas Covered: The future severe asthma-decision trees should revisit current knowledge and gaps. A focused literature search has been conducted., Expert Opinion: Asthma severity is currently defined a priori , thereby precluding a role for early interventions aiming to prevent outcomes such as exacerbations (systemic corticosteroids exposure) and lung function decline. Asthma 'at-risk' might represent the ultimate paradigm but merits longitudinal studies considering modern interventions. Real exacerbations, severe airway hyperresponsiveness, excessive T2-related biomarkers, noxious environments and patient behaviors, harms of OCS and high-doses inhaled corticosteroids (ICS), and low adherence-to-effectiveness ratios of ICS-containing inhalers are predictors of future risks. New tools such as imaging, genetic, and epigenetic signatures should be used. Logical and numerical artificial intelligence may be used to generate a consistent risk score. A pragmatic definition of response to treatments will allow development of a validated and applicable algorithm. Biologics have the best potential to minimize the risks, but cost remains an issue. We propose a simplified six-step algorithm for decision-making that is ultimately aiming to achieve asthma remission.
- Published
- 2024
- Full Text
- View/download PDF
35. Association between pre-biologic T2-biomarker combinations and response to biologics in patients with severe asthma.
- Author
-
Porsbjerg CM, Townend J, Bergeron C, Christoff GC, Katsoulotos GP, Larenas-Linnemann D, Tran TN, Al-Lehebi R, Bosnic-Anticevich SZ, Busby J, Hew M, Kostikas K, Papadopoulos NG, Pfeffer PE, Popov TA, Rhee CK, Sadatsafavi M, Tsai MJ, Ulrik CS, Al-Ahmad M, Altraja A, Beastall A, Bulathsinhala L, Carter V, Cosio BG, Fletton K, Hansen S, Heaney LG, Hubbard RB, Kuna P, Murray RB, Nagano T, Pini L, Cano Rosales DJ, Schleich F, Wechsler ME, Amaral R, Bourdin A, Brusselle GG, Chen W, Chung LP, Denton E, Fonseca JA, Hoyte F, Jackson DJ, Katial R, Kirenga BJ, Koh MS, Ławkiedraj A, Lehtimäki L, Liew MF, Mahboub B, Martin N, Menzies-Gow AN, Pang PH, Papaioannou AI, Patel PH, Perez-De-Llano L, Peters MJ, Ricciardi L, Rodríguez-Cáceres B, Solarte I, Tay TR, Torres-Duque CA, Wang E, Zappa M, Abisheganaden J, Assing KD, Costello RW, Gibson PG, Heffler E, Máspero J, Nicola S, Perng Steve DW, Puggioni F, Salvi S, Sheu CC, Sirena C, Taillé C, Tan TL, Bjermer L, Canonica GW, Iwanaga T, Jiménez-Maldonado L, Taube C, Brussino L, and Price DB
- Subjects
- Humans, Male, Female, Middle Aged, Adult, Anti-Asthmatic Agents therapeutic use, Treatment Outcome, Registries, Severity of Illness Index, Leukocyte Count, Nitric Oxide metabolism, Aged, Cohort Studies, Asthma drug therapy, Asthma diagnosis, Asthma immunology, Biomarkers, Immunoglobulin E blood, Immunoglobulin E immunology, Eosinophils immunology, Biological Products therapeutic use
- Abstract
Background: To date, studies investigating the association between pre-biologic biomarker levels and post-biologic outcomes have been limited to single biomarkers and assessment of biologic efficacy from structured clinical trials., Aim: To elucidate the associations of pre-biologic individual biomarker levels or their combinations with pre-to-post biologic changes in asthma outcomes in real-life., Methods: This was a registry-based, cohort study using data from 23 countries, which shared data with the International Severe Asthma Registry (May 2017-February 2023). The investigated biomarkers (highest pre-biologic levels) were immunoglobulin E (IgE), blood eosinophil count (BEC) and fractional exhaled nitric oxide (FeNO). Pre- to approximately 12-month post-biologic change for each of three asthma outcome domains (i.e. exacerbation rate, symptom control and lung function), and the association of this change with pre-biologic biomarkers was investigated for individual and combined biomarkers., Results: Overall, 3751 patients initiated biologics and were included in the analysis. No association was found between pre-biologic BEC and pre-to-post biologic change in exacerbation rate for any biologic class. However, higher pre-biologic BEC and FeNO were both associated with greater post-biologic improvement in FEV
1 for both anti-IgE and anti-IL5/5R, with a trend for anti-IL4Rα. Mean FEV1 improved by 27-178 mL post-anti-IgE as pre-biologic BEC increased (250 to 1000 cells/µL), and by 43-216 mL and 129-250 mL post-anti-IL5/5R and -anti-IL4Rα, respectively along the same BEC gradient. Corresponding improvements along a FeNO gradient (25-100 ppb) were 41-274 mL, 69-207 mL and 148-224 mL for anti-IgE, anti-IL5/5R, and anti-IL4Rα, respectively. Higher baseline BEC was also associated with lower probability of uncontrolled asthma (OR 0.392; p=0.001) post-biologic for anti-IL5/5R. Pre-biologic IgE was a poor predictor of subsequent pre-to-post-biologic change for all outcomes assessed for all biologics. The combination of BEC + FeNO marginally improved the prediction of post-biologic FEV1 increase (adjusted R2 : 0.751), compared to BEC (adjusted R2 : 0.747) or FeNO alone (adjusted R2 : 0.743) (p=0.005 and <0.001, respectively); however, this prediction was not improved by the addition of IgE., Conclusions: The ability of higher baseline BEC, FeNO and their combination to predict biologic-associated lung function improvement may encourage earlier intervention in patients with impaired lung function or at risk of accelerated lung function decline., Competing Interests: CP has attended advisory boards for AstraZeneca, Novartis, TEVA, and Sanofi-Genzyme; has given lectures at meetings supported by AstraZeneca, Novartis, TEVA, Sanofi-Genzyme, and GlaxoSmithKline; has taken part in clinical trials sponsored by AstraZeneca, Novartis, MSD, Sanofi-Genzyme, GlaxoSmithKline, and Novartis; and has received educational and research grants from AstraZeneca, Novartis, TEVA, GlaxoSmithKline, ALK, and Sanofi-Genzyme. JT is an employee of the Observational and Pragmatic Research Institute OPRI. OPRI conducted this study in collaboration with Optimum Patient Care and AstraZeneca. CB reports advisory board participation of Sanofi-Regeneron, AstraZeneca, Takeda, ValeoPharma, honorarium for presentations for AstraZeneca/Amgen, GlaxoSmithKline, Grifols, Sanofi-Regeneron, ValeoPharma and grants paid to UBC from BioHaven, Sanofi-Regeneron, AstraZeneca, GlaxoSmithKline. GCC declares relevant research support from AstraZeneca and Sanofi. GK has attended advisory boards for AstraZeneca, GlaxoSmithKline and Chiesi. He has also given lectures at meetings supported by Novartis, Sanofi-Genzyme, AstraZeneca, GlaxoSmithKline, and Boehringer-Ingelheim. DL reports personal fees from ALK-Abelló, AstraZeneca national and global, Bayer, Chiesi, Grunenthal, Grin, GlaxoSmithKline national and global, Viatris, Menarini, MSD, Novartis, Pfizer, Sanofi, Siegfried, UCB, Carnot, grants from Abbvie, Bayer, Lilly, Sanofi, AstraZeneca, Pfizer, Novartis, Circassia, UCB, GlaxoSmithKline, outside the submitted work. TNT is an employee of AstraZeneca and may own stock or stock options in AstraZeneca. AstraZeneca is a co-funder of ISAR. RA-L has given lectures at meetings supported by AstraZeneca, Boehringer Ingelheim, Novartis, GlaxoSmithKline, and Sanofi, and participated in advisory board fees from GlaxoSmithKline, AstraZeneca, Novartis, and Abbott. SB-A has received honorarium for participation in expert advisory boards and given lectures for Teva Pharmaceuticals, AstraZeneca, GlaxoSmithKline, Meda, Mundipharma, Sanofi, Mylan and received unrestricted research grants from Mylan, AstraZeneca, Teva, Mundipharma International, GlaxoSmithKline, and Viatris. JB has received research grants from AstraZeneca and personnel fees from NuvoAir, outside the submitted work. MH declares grants and other advisory board fees made to his institutional employer from AstraZeneca, GlaxoSmithKline, Novartis, Sanofi, Teva, and Seqirus, for unrelated projects. KK received honoraria for presentations and consultancy fees from AstraZeneca, Boehringer Ingelheim, CSL Behring, Chiesi, ELPEN, Gilead, GlaxoSmithKline, Menarini, Novartis, Sanofi, Specialty Therapeutics, WebMD. His department has received funding and grants from AstraZeneca, Boehringer Ingelheim, Chiesi, Innovis, ELPEN, GlaxoSmithKline, Menarini, Novartis and NuvoAir. NP has been a speaker and/or advisory board member for Abbott, Abbvie, ALK, Asit Biotech, AstraZeneca, Biomay, Boehringer Ingelheim, GlaxoSmithKline, HAL, Faes Farma, Medscape, Menarini, MSD, Novartis, Nutricia, OM Pharma, Regeneron, Sanofi, Takeda, and Viatris. PEP has attended advisory boards for AstraZeneca, GlaxoSmithKline, and Sanofi; has given lectures/webinars at meetings supported by AstraZeneca, Chiesi and GlaxoSmithKline; has taken part in clinical trials sponsored by AstraZeneca, GlaxoSmithKline, Novartis, Regeneron, and Sanofi, for which his institution received remuneration; and has a current research grant funded by GlaxoSmithKline. TP declares relevant research support from Novartis and Chiesi Pharma. CR received consulting/lecture fees from MSD, AstraZeneca, GlaxoSmithKline, Novartis, Takeda, Mundipharma, Boehringer-Ingelheim, Teva, Sanofi, and Bayer. MS has received honoraria from AstraZeneca, Boehringer Ingelheim, Teva, and GlaxoSmithKline for purposes unrelated to the content of this manuscript and has received research funding from AstraZeneca and Boehringer Ingelheim directly into his research account from AstraZeneca for unrelated projects. M-JT has received sponsorship to attend or speak at conferences, honoraria for lecturing or attending advisory boards, and research grants from the following companies: AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Pfizer, Shionogi and Orient EuroPharma. CU reports personal fees for talks, participation in advisory boards etc. from AstraZeneca, GlaxoSmithKline, Teva, Boehringer Ingelheim, Orion Pharma, Sanofi Genzyme, TFF Pharmaceuticals, Covis Pharma, Berlin-Chemie, Takeda, Chiesi, and Pfizer, outside the submitted work. MA-A has received advisory board and speaker fees from AstraZeneca, Sanofi, Novartis, and GlaxoSmithKline and received a grant from Kuwait Foundation for the Advancement of Sciences KFAS. AA has received lecture fees from AstraZeneca, Berlin-Chemie Menarini, Boehringer Ingelheim, CSL Behring, GlaxoSmithKline, MSD, Norameda, Novartis, Orion, Sanofi, and Zentiva; sponsorships from AstraZeneca, Berlin-Chemie Menarini, Boehringer Ingelheim, GlaxoSmithKline, MSD, Norameda, Novartis, and Sanofi; and has participated in advisory boards for AstraZeneca, Boehringer Ingelheim, CSL Behring, GlaxoSmithKline, MSD, Novartis, Sanofi, and Teva. ABe is an employee of Optimum Patient Care Global, a co-funder of the International Severe Asthma Registry. LBu is an employee of the Observational and Pragmatic Research Institute OPRI. OPRI conducted this study in collaboration with Optimum Patient Care and AstraZeneca. VC is an employee of Optimum Patient Care OPC. OPC is a co-funder of the International Severe Asthma Registry. BC declares grants from Chiesi and GlaxoSmithKline; personal fees for advisory board activities from Chiesi, GlaxoSmithKline, Novartis, Sanofi, Teva, and AstraZeneca; and payment for lectures/speaking engagements from Chiesi, Novartis, GlaxoSmithKline, Menarini, and AstraZeneca, outside the submitted work. KF is an employee of Optimum Patient Care Global OPCG, a co-funder of the International Severe Asthma Registry. LH has received grant funding, participated in advisory boards and given lectures at meetings supported by Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Circassia, Hoffmann la Roche, GlaxoSmithKline, Novartis, Theravance, Evelo Biosciences, Sanofi, and Teva; he has received grants from MedImmune, Novartis UK, Roche/Genentech Inc, and GlaxoSmithKline, Amgen, Genentech/Hoffman la Roche, AstraZeneca, MedImmune, GlaxoSmithKline, Aerocrine, and Vitalograph; he has received sponsorship for attending international scientific meetings from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, and Napp Pharmaceuticals; he has also taken part in asthma clinical trials sponsored by AstraZeneca, Boehringer Ingelheim, Hoffmann la Roche, and GlaxoSmithKline for which his institution received remuneration; he is the Academic Lead for the Medical Research Council Stratified Medicine UK Consortium in Severe Asthma which involves industrial partnerships with a number of pharmaceutical companies including Amgen, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Hoffmann la Roche, and Janssen. RH is an employee for Observational and Pragmatic Research Institute OPRI which conducted this study in collaboration with Optimum Patient Care and AstraZeneca. PK reports personal fees from Adamed, AstraZeneca, Berlin Chemie Menarini, FAES, Glenmark, Novartis, Polpharma, Boehringer Ingelheim, Teva, Zentiva, outside the submitted work. RM is a consultant for Observational and Pragmatic Research Institute OPRI which conducted this study in collaboration with Optimum Patient Care and AstraZeneca. TN received lecture fees from Kyorin, GlaxoSmithKline, Novartis, Sanofi, and AstraZeneca. LP received research grants and lecture fees from GlaxoSmithKline, Menarini, Chiesi, AstraZeneca and Grifols. DC has received speaker fees from AstraZeneca, Boehringer Ingelheim, and has acted as an investigator for trials sponsored by AstraZeneca. FS reports consultancy work for GlaxoSmithKline, AstraZeneca, Sanofi - Advisory board, received speaker fees from GlaxoSmithKline, AstraZeneca, Chiesi, Amgen, Teva and research grants from GlaxoSmithKline, AstraZeneca, and Chiesi. MW reports grants and/or personal fees from Novartis, Sanofi, Regeneron, Genentech, Sentien, Restorbio, Equillium, Genzyme, Cohero Health, Teva, Boehringer Ingelheim, AstraZeneca, Amgen, GlaxoSmithKline, Cytoreason, Cerecor, Sound Biologics, Incyte, and Kinaset. ABo has received industry-sponsored grants from AstraZeneca/MedImmune, Boehringer-Ingelheim, Cephalon/Teva, GlaxoSmithKline, Novartis, Sanofi-Regeneron, and consultancies with AstraZeneca/MedImmune, Boehringer-Ingelheim, GlaxoSmithKline, Novartis, Regeneron-Sanofi, Med-in-Cell, Actelion, Merck, Roche, and Chiesi. GB has received honoraria for lectures from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, and Novartis. He is a member of advisory boards for AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, MSD Merck sharp & Dohme, Novartis, and Sanofi/Regeneron. LC has received speaker and consultancy fees and conference expenses from AstraZeneca, Novartis, GlaxoSmithKline, Boehringer Ingelheim and Menarini. ED declares grants to her institution from AstraZeneca, GlaxoSmithKline, Novartis, Sanofi, Teva, and Seqirus, for unrelated projects and speaker fees from Sanofi. JF reports grants from research agreements with AstraZeneca, Mundipharma, Sanofi Regeneron, and Novartis. Personal fees for lectures and attending advisory boards: AstraZeneca, GlaxoSmithKline, Mundipharma, Novartis, Sanofi Regeneron, and Teva. FH declares honoraria from AstraZeneca, Sanofi, TEVA, GSK, and Genentech. She has been an investigator on clinical trials sponsored by GlaxoSmithKline, Genentech, and Sanofi, for which her institution has received funding. DJ has received speaker fees and consultancy fees from AstraZeneca, GlaxoSmithKline, Sanofi Regeneron, Boehringer Ingelheim and research funding from AstraZeneca. MK reports grant support from AstraZeneca, and honoraria for lectures and advisory board meetings paid to her hospital Singapore General Hospital from GlaxoSmithKline, AstraZeneca, Novartis, Sanofi and Boehringer Ingelheim, outside the submitted work. LL has received personal fees from ALK, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Menarini, Novartis, Orion Pharma and Sanofi. NM is an employee of AstraZeneca and may own stock or stock options in AstraZeneca. AstraZeneca is a co-funder of ISAR. AM-G is an employee of AstraZeneca and may own stock or stock options in AstraZeneca. AstraZeneca is a co-funder of ISAR. PHwP has received honoraria for talks and advisory board meetings from GlaxoSmithKline, AstraZeneca, and Sanofi. AP has received fees and honoraria from Menarini, GlaxoSmithKline, Novartis, Elpen, Boehringer Ingelheim, AstraZeneca, and Chiesi. PHP has received advisory board and speaker fees from AstraZeneca, GlaxoSmithKline, Novartis, and Sanofi/Regeneron. LP-d-L reports grants, personal fees and non-financial support from AstraZeneca, personal fees and non-financial support from GlaxoSmithKline, grants, personal fees and non-financial support from Teva, personal fees and non-financial support from Chiesi, grants, personal fees and non-financial support from Sanofi, personal fees from MSD, personal fees from Techdow Pharma, grants, personal fees and non-financial support from Faes Farma, personal fees from Leo-Pharma, grants and personal fees from Gebro, personal fees from Gilead, outside the submitted work. MP declares personal fees and non-financial support from AstraZeneca, GlaxoSmithKline, and Sanofi. LR received fees as a speaker from AstraZeneca, GlaxoSmithKline, Novartis, and Sanofi. IS has received fees as advisory board participant and/or speaker from GlaxoSmithKline and Sanofi. CT-D has received fees as advisory board participant and/or speaker from AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Novartis, and Sanofi-Aventis; has taken part in clinical trials from AstraZeneca, Novartis, and Sanofi-Aventis; has received unrestricted grants for investigator-initiated studies at Fundacion Neumologica Colombiana from AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Grifols and Novartis. EW has received honoraria from AstraZeneca, GlaxoSmithKline, and Genentech. She has been an investigator on studies sponsored by AstraZeneca, GlaxoSmithKline, Genentech, Sanofi, Novartis, and Teva, for which her institution has received funding. RC has received honoraria for lectures from Aerogen, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, and Teva. He is a member of advisory boards for GlaxoSmithKline and Novartis, has received grant support from GlaxoSmithKline and Aerogen and has patents in the use of acoustics in the diagnosis of lung disease, assessment of adherence and prediction of exacerbations. PG has received speaker fees and grants to his institution from AstraZeneca, GlaxoSmithKline, and Novartis. EH declares personal fees for advisory boards participation and/or speaker activities from: Sanofi, Regeneron, GlaxoSmithKline, Novartis, AstraZeneca, Stallergenes-Greer, Circassia, Bosch, Celltrion-Healthcare, Chiesi, and Almirall. JM reports speaker fees, grants or advisory boards for AstraZeneca, Sanofi, GlaxoSmithKline, Novartis, Inmunotek, Menarini and Noucor. D-WP received sponsorship to attend or speak at international meetings, honoraria for lecturing or attending advisory boards, and research grants from the following companies: AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Daiichi Sankyo, Shionogi, and Orient Pharma. FP reports having received lectures or advisory board fees from: Menarini, Mundipharma, Chiesi, Alk Abello, AstraZeneca, Boehringer Ingelheim, Guidotti, Malesci, GlaxoSmithKline, Hal Allergy, Novartis, Sanofi, Regeneron, Stallergenes Greer, Valeas, and Almirall. SS declares research support and speaker fees from Cipla, Glenmark, and GlaxoSmithKline. C-CS has received speaker fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, and Pfizer, and has acted as an investigator for trials sponsored by AstraZeneca, Novartis, Roche, Sanofi-Regeneron, Galapagos, Shionogi, Aridis, Bristol Myers Squibb, Insmed, United Therapeutics, Enanta Pharmaceuticals, Areteia Therapeutics, Meiji, and Horizon Therapeutics. CT has received lecture or advisory board fees and grants to her institution from AstraZeneca, Sanofi, GlaxoSmithKline, Chiesi and Novartis, for unrelated projects. TT is an advisory Board Member for Boehringer Ingelheim, AstraZeneca, Takeda, GlaxoSmithKline, MSD, Mundipharma, and Janssen. Honoraria were received for these advisory boards. Honoraria were received for speaking at CMEs for AstraZeneca in the past. Conference sponsorships from AstraZeneca, Boehringer Ingelheim, Merck Serono, GlaxoSmithKline, Norvatis, Mundipharma and MSD. Research grants from Merck Serono Concor Study, MSD Apbord study. LBj has in the last three years received lecture or advisory board fees from Alk-Abello, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Mundipharma, Novartis, Sanofi, Genzyme/Regeneron, and Teva. GWC has received research grants, as well as lecture or advisory board fees from A. Menarini, Alk-Albello, Allergy Therapeutics, Anallergo, AstraZeneca, MedImmune, Boehringer Ingelheim, Chiesi Farmaceutici, Circassia, Danone, Faes, Genentech, Guidotti Malesci, GlaxoSmithKline, Hal Allergy, Merck, MSD, Mundipharma, Novartis, Orion, Sanofi Aventis, Sanofi, Genzyme/Regeneron, Stallergenes, UCB Pharma, Uriach Pharma, Teva, Thermo Fisher, and Valeas. TI received speaker bureau fees from Kyorin, GlaxoSmithKline, Novartis, Boehringer Ingelheim, AstraZeneca and Sanofi. LJ-M has received fees as advisory board participant and/or speaker from AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Novartis, and Sanofi-Aventis; has participated in clinical trials for AstraZeneca, Novartis, and GlaxoSmithKline. DP has advisory board membership with AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis, Viatris, Teva Pharmaceuticals; consultancy agreements with AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis, Viatris, Teva Pharmaceuticals; grants and unrestricted funding for investigator-initiated studies conducted through Observational and Pragmatic Research Institute Pte Ltd from AstraZeneca, Chiesi, Viatris, Novartis, Regeneron Pharmaceuticals, Sanofi Genzyme, and UK National Health Service; payment for lectures/speaking engagements from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Commune Digital, GlaxoSmithKline, Medscape, Viatris, Novartis, Regeneron Pharmaceuticals and Sanofi Genzyme, Teva Pharmaceuticals; payment for travel/accommodation/meeting expenses from AstraZeneca, Boehringer Ingelheim, Novartis, Medscape, Teva Pharmaceuticals; stock/stock options from AKL Research and Development Ltd which produces phytopharmaceuticals; owns 74% of the social enterprise Optimum Patient Care Ltd Australia and UK and 92.61% of Observational and Pragmatic Research Institute Pte Ltd Singapore; 5% shareholding in Timestamp which develops adherence monitoring technology; is peer reviewer for grant committees of the UK Efficacy and Mechanism Evaluation Programme, and Health Technology Assessment; and was an expert witness for GlaxoSmithKline. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Porsbjerg, Townend, Bergeron, Christoff, Katsoulotos, Larenas-Linnemann, Tran, Al-Lehebi, Bosnic-Anticevich, Busby, Hew, Kostikas, Papadopoulos, Pfeffer, Popov, Rhee, Sadatsafavi, Tsai, Ulrik, Al-Ahmad, Altraja, Beastall, Bulathsinhala, Carter, Cosio, Fletton, Hansen, Heaney, Hubbard, Kuna, Murray, Nagano, Pini, Cano Rosales, Schleich, Wechsler, Amaral, Bourdin, Brusselle, Chen, Chung, Denton, Fonseca, Hoyte, Jackson, Katial, Kirenga, Koh, Ławkiedraj, Lehtimäki, Liew, Mahboub, Martin, Menzies-Gow, Pang, Papaioannou, Patel, Perez-De-Llano, Peters, Ricciardi, Rodríguez-Cáceres, Solarte, Tay, Torres-Duque, Wang, Zappa, Abisheganaden, Assing, Costello, Gibson, Heffler, Máspero, Nicola, Perng (Steve), Puggioni, Salvi, Sheu, Sirena, Taillé, Tan, Bjermer, Canonica, Iwanaga, Jiménez-Maldonado, Taube, Brussino and Price.)- Published
- 2024
- Full Text
- View/download PDF
36. Association Between T2-related Comorbidities and Effectiveness of Biologics in Severe Asthma.
- Author
-
Wechsler ME, Scelo G, Larenas-Linnemann DES, Torres-Duque CA, Maspero J, Tran TN, Murray RB, Martin N, Menzies-Gow AN, Hew M, Peters MJ, Gibson PG, Christoff GC, Popov TA, Côté A, Bergeron C, Dorscheid D, FitzGerald JM, Chapman KR, Boulet LP, Bhutani M, Sadatsafavi M, Jiménez-Maldonado L, Duran-Silva M, Rodriguez B, Celis-Preciado CA, Cano-Rosales DJ, Solarte I, Fernandez-Sanchez MJ, Parada-Tovar P, von Bülow A, Bjerrum AS, Ulrik CS, Assing KD, Rasmussen LM, Hansen S, Altraja A, Bourdin A, Taille C, Charriot J, Roche N, Papaioannou AI, Kostikas K, Papadopoulos NG, Salvi S, Long D, Mitchell PD, Costello R, Sirena C, Cardini C, Heffler E, Puggioni F, Canonica GW, Guida G, Iwanaga T, Al-Ahmad M, García U, Kuna P, Fonseca JA, Al-Lehebi R, Koh MS, Rhee CK, Cosio BG, Perez de Llano L, Perng DS, Huang EW, Wang HC, Tsai MJ, Mahboub B, Salameh LIJ, Jackson DJ, Busby J, Heaney LG, Pfeffer PE, Goddard AG, Wang E, Hoyte FCL, Chapman NM, Katial R, Carter V, Bulathsinhala L, Eleangovan N, Ariti C, Lyu J, Porsbjerg C, and Price DB
- Subjects
- Adult, Humans, Cohort Studies, Comorbidity, Chronic Disease, Rhinitis complications, Rhinitis drug therapy, Rhinitis epidemiology, Asthma complications, Asthma drug therapy, Asthma epidemiology, Sinusitis drug therapy, Sinusitis epidemiology, Biological Products therapeutic use, Rhinitis, Allergic complications, Rhinitis, Allergic drug therapy, Rhinitis, Allergic epidemiology, Nasal Polyps complications, Nasal Polyps drug therapy, Nasal Polyps epidemiology
- Abstract
Rationale: Previous studies investigating the impact of comorbidities on the effectiveness of biologic agents have been relatively small and of short duration and have not compared classes of biologic agents. Objectives: To determine the association between type 2-related comorbidities and biologic agent effectiveness in adults with severe asthma (SA). Methods: This cohort study used International Severe Asthma Registry data from 21 countries (2017-2022) to quantify changes in four outcomes before and after biologic therapy-annual asthma exacerbation rate, FEV
1 % predicted, asthma control, and long-term oral corticosteroid daily dose-in patients with or without allergic rhinitis, chronic rhinosinusitis (CRS) with or without nasal polyps (NPs), NPs, or eczema/atopic dermatitis. Measurements and Main Results: Of 1,765 patients, 1,257, 421, and 87 initiated anti-IL-5/5 receptor, anti-IgE, and anti-IL-4/13 therapies, respectively. In general, pre- versus post-biologic therapy improvements were noted in all four asthma outcomes assessed, irrespective of comorbidity status. However, patients with comorbid CRS with or without NPs experienced 23% fewer exacerbations per year (95% CI, 10-35%; P < 0.001) and had 59% higher odds of better post-biologic therapy asthma control (95% CI, 26-102%; P < 0.001) than those without CRS with or without NPs. Similar estimates were noted for those with comorbid NPs: 22% fewer exacerbations and 56% higher odds of better post-biologic therapy control. Patients with SA and CRS with or without NPs had an additional FEV1 % predicted improvement of 3.2% (95% CI, 1.0-5.3; P = 0.004), a trend that was also noted in those with comorbid NPs. The presence of allergic rhinitis or atopic dermatitis was not associated with post-biologic therapy effect for any outcome assessed. Conclusions: These findings highlight the importance of systematic comorbidity evaluation. The presence of CRS with or without NPs or NPs alone may be considered a predictor of the effectiveness of biologic agents in patients with SA.- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.